[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Linkoeping\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":260},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,74,102,134,159,182,208,235],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643229","the-effect-of-nasogastric-tube-placement-on-complications-in-patients-with-small-bowel-obstruction---the-sbo-tube-trial-100643229",false,"NCT07574515","The Effect of Nasogastric Tube Placement on Complications in Patients With Small Bowel Obstruction - the SBO-TUBE Trial","The Effect of Nasogastric Tube Placement on Complications in Patients With Small Bowel Obstruction - the SBO-TUBE Randomized Controlled Trial","SBO-TUBE","Inclusion Criteria:\n\n* Small bowel obstruction diagnosed on Computer Tomography\n\nExclusion Criteria:\n\n* Nasogastric Tube already places\n* Amyotrophic lateral sclerosis\n* Cerebral palsy\n* Dementia\n* Parkinson's disease\n* Multiple Sclerosis\n* Previous stroke with documented persistent dysphagia\n* Planned for urgent surgery\n* Acute Massive Gastric Dilatation\n* Gastric outlet obstruction\n* Fundoplicatio\u002FInability to vomit\n* Signs of pneumonia\u002Fpneumonitis on initial diagnostic CT","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background: Small bowel obstruction (SBO) is a surgical emergency where the normal continuous bowel movements are hindered and approximately 8000-9000 patients visit the emergency department every year in Sweden due to SBO. A minority of these have evidence of intestinal injury, warranting emergency surgery, while the majority (70-90%) will have an initial plan for non-operative management with a nasogastric tube (NGT), placed to alleviate gastric pressure, reduce pain and prevent complications like aspiration pneumonia. The effectiveness of NGT in patients with SBO to prevent complications is unclear, with current data from observational data indicating increased risk of pneumonia in patients treated with NGT. Objective: To assess whether deferring the placement of a NGT in subjects with small bowel obstruction and planned for non-operative management leads to lower rates of respiratory complication compared to placing an NGT. Methods: This will be a randomized, controlled, open-label, multicenter study of patients with SBO and an initial plan for non-operative management. Patients will be randomized in a 1:1 ratio to not receive an NGT (intervention) or receive an NGT (control) and monitored regularly until the SBO resolves spontaneously or through surgery, whichever comes first. The primary outcome will be a composite of pulmonary complications and treatment in a high dependency unit, analyzed as a superiority study with an intention-to-treat framework with secondary per-protocol and non-inferiority analysis. The trial will recruit 1000 patients. Secondary analysis includes health-economy, qualitative interviews, and long term (1 year) follow up. Discussion: The current management of NGT in SBO is based on clinical and guideline-based recommendations with limited supporting data. Available data, albeit observational with risk for selection bias, indicates increased risk of complications. This equipoise warrants further investigation to understand the true benefit of NGT in SBO. This study will provide high quality evidence of the ability of a NGT to prevent complications in SBO through its randomized, prospective design",[27,28],"Small Bowel Obstruction","Intestinal Obstruction and Ileus",[30,31,32],"ileus","small bowel obstruction","nasogastric tube","RECRUITING","2026-06-08",{"date":36,"type":37},"2026-06-11","ACTUAL",{"date":39,"type":37},"2026-05-27",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"University Hospital, Linkoeping","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100461124","phase-2-tinzaparin-and-biomarkers-after-neoadjuvant-treatment-of-ovarian-cancer-100461124","NCT05284552","Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","The Effect of Tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy - A Randomized Pilot Study","Inclusion Criteria:\n\n* The subject has given written consent to participate in the study.\n* Age 18 and above\n* Epithelial ovarian, fallopian tube or peritoneal cancer, or abdominal cancer where a biopsy indicates an origin from the ovary, fallopian tube or peritoneum.\n* Histology diagnosis of either high grade serous carcinoma, endometroid carcinoma or clear cell carcinoma.\n* FIGO stage III-IV disease.\n* Planned for platinum-based chemotherapy\n* Prior to start of NACT pregnancy should be ruled out by menstrual history or in unclear cases by a urine hCG test.\n* Women of childbearing potential should use a safe birth control method (combined hormonal contraception, progesterone only hormonal contraception, intra uterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence, male or female condom, diaphragm with spermicide).\n* WHO Performance Status 0-2\n* Weight 50-150 kg\n* CA-125-level ≥250 kIE\u002FL at diagnosis\n\nExclusion Criteria:\n\n* Concomitant treatment with heparins, low molecular weight heparins, warfarin or non-vitamin K antagonist oral anticoagulants. Platelet inhibitors are allowed.\n* Treatment with heparins, low molecular weight heparins or non-vitamin K antagonist oral anticoagulants within the last year.\n* Known or suspected allergies against any product included in the study\n* Ongoing pregnancy, independent of gestational age. Breastfeeding or planned pregnancy\n* EOC disclosed at Cesarean section\n* Abdominal surgery or other major surgery within the last year\n* Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation\n* Treatment or disease which, according to the investigator, can affect treatment or study results\n* Known brain metastasis\n* Participation or recent participation (within the last 30 days) in a clinical study with an investigational product\n* Ongoing treatment of thromboembolic disease.\n* Thromboembolic disease within the last year.\n* Hypersensitivity to the active substance (tinzaparin) or any of the excipients.\n* Serious hemorrhage or conditions predisposing to serious hemorrhage. Serious hemorrhage is defined as fulfilling any one of these three criteria:\n\n  1. occurs in a critical area or organ (e.g. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, intra-uterine or intramuscular with compartment syndrome),\n  2. causes a fall in hemoglobin level of 20 g\u002FL (1.24 mmol\u002FL) or more, or\n  3. leads to transfusion of two or more units of whole blood or red blood cells.\n* Severe coagulation disorder.\n* Acute gastro duodenal ulcer.\n* Septic endocarditis.\n* Previous heparin-induced thrombocytopenia.\n* WHO Performance Status \\>2.\n* E-GFR \\\u003C30ml\u002Fmin (analyzed no more than 14 days before start of treatment with investigational product)\n* Platelets \\\u003C100 x10\\^9\u002FL (analyzed no more than 14 days before start of treatment with investigational product)\n* Treatment for other known malignancy within the last year (except basal cell carcinoma)","FEMALE",{"count":55,"type":21},40,[57],"PHASE2","Background:\n\nPrevious findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC).\n\nStudy objectives:\n\nPrimary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (NACT).\n\nSecondary objectives: The secondary objective of the study is to explore the impact of tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse events caused by tinzaparin will be described.",[60],"Epithelial Ovarian Cancer",[62,63,64],"Tinzaparin","Neoadjuvant chemotherapy","FIGO stage III-IV","2026-05-06",{"date":67,"type":37},"2026-05-11",{"date":69,"type":37},"2022-07-12",{"date":71,"type":21},"2027-12",{"name":43,"class":44},8,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100631311","evaluation-of-the-diagnostic-performance-of-the-testicular-workup-for-ischemia-and-suspected-torsion-twist-score-for-assessing-the-risk-of-testicular-torsion-in-adult-patients-presenting-to-the-emergency-department-with-scrotal-pain---a-prospective-observational-study-100631311","NCT07499024","Evaluation of the Diagnostic Performance of the Testicular Workup for Ischemia and Suspected Torsion (TWIST) Score for Assessing the Risk of Testicular Torsion in Adult Patients Presenting to the Emergency Department With Scrotal Pain - A Prospective Observational Study","Evaluation of the Diagnostic Performance of the Testicular Workup for Ischemia and Suspected Torsion (TWIST) Score for Assessing the Risk of Testicular Torsion in Adult Patients Presenting to the Emergency Department With Scrotal Pain","Inclusion Criteria:\n\n* Male patients aged 18-40 years\n\nPresenting to the Emergency Department with acute scrotal pain or scrotal symptoms\n\nSuspicion of testicular torsion before clinical assessment\n\nExclusion Criteria:\n\n* Scrotal pain or symptoms caused by trauma\n\nSymptom duration \\> 1 week\n\nHistory of testicular surgery\n\nInability to provide informed consent (e.g., language barrier or cognitive limitation)","MALE","40 Years",{"count":20,"type":21},"30 Days","OBSERVATIONAL","This prospective multicenter observational study aims to evaluate the diagnostic accuracy of the Testicular Workup for Ischemia and Suspected Torsion (TWIST) score in adult patients presenting with acute scrotal pain in Swedish Emergency Departments.\n\nThe TWIST score is a clinical decision tool originally validated in pediatric populations to stratify patients into low, intermediate, and high risk for testicular torsion. The study will include men aged 18-40 years presenting with scrotal pain or symptoms suggestive of torsion. Patients with scrotal trauma, symptom duration over one week, previous testicular surgery, or inability to give informed consent in Swedish will be excluded.\n\nParticipants' clinical findings will be recorded on a standardized form, and the TWIST score will be calculated. Management will follow standard clinical practice independently of the study. Primary outcome is the diagnostic accuracy of the TWIST score to rule out testicular torsion in low-risk patients (TWIST 0-2). Secondary outcomes include diagnosis of torsion within 30 days, time to surgery, patient-reported pain, number of Doppler ultrasounds performed, and the potential reduction in unnecessary imaging.\n\nThe study will be conducted at multiple Swedish sites, including Linköping University Hospital, under oversight by the Swedish Ethical Review Authority (Etikprövningsmyndigheten, decision number 2025-07400-01). The results aim to inform clinical practice by providing a validated decision-support tool for adult patients with suspected testicular torsion, potentially improving patient outcomes and resource utilization.",[88,89,90],"Testicular Torsion","Acute Scrotum","Scrotal Pain",[88,89,92],"Testicular Workup for Ischemia and Suspected Torsion (TWIST)","2026-04-23",{"date":95,"type":37},"2026-04-29",{"date":97,"type":37},"2026-02-01",{"date":99,"type":21},"2029-12-31",{"name":43,"class":44},1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100621219","patient-education-in-osteoporosis-rct-patos-100621219","NCT07367776","Patient Education in Osteoporosis (RCT-PATOS)","Effects and Mechanisms of Patient Education in Osteoporosis: A Randomized Controlled Trial Comparing Digital Education, Face-to-Face Education, and General Patient Information (RCT-PATOS)","RCT-PATOS","Inclusion Criteria:\n\n* Women and men\n* Age \\> 50 years\n* Diagnosed with osteoporosis or osteopenia (either ICD-coded \\[M80x, M81x, or M859\\] or current\u002Fprevious pharmacological treatment for osteoporosis)\n* Basic computer literacy\n* Possession of BankID (Swedish electronic identification system used for secure authentication) and ability to log in to the 1177.se \"Support and Treatment platform\"\n\nExclusion Criteria:\n\n* Inability to understand written and spoken Swedish\n* Cognitive impairment preventing comprehension of the study protocol and provision of informed consent\n* Participation in structured patient education on osteoporosis within the past year","50 Years",{"count":112,"type":21},600,[24],"The objective of this randomized clinical trial is to assess both the effectiveness and underlying mechanisms of patient education for individuals aged 50 years and older with osteoporosis.\n\nPrimary research question: What differences in outcomes can be observed among three different educational interventions with respect to osteoporosis-specific self-care, health related quality of life, fracture risk, illness perception, physical activity, physical function, fear of falling, and pain in patients diagnosed with osteoporosis?\n\nThe trial will include three study arms: 1) Control group: Participants receive standard osteoporosis information provided by healthcare services. 2) Face-to-face education: Three 2-hours sessions led by a physiotherapist (two sessions) and physician or nurse (one session) within a 2 months period. 3) Digital education: Internet-based program consisting of nine modules accessible to participants over a one-year period.\n\nParticipants will complete questionnaires and undergo physical assessments at baseline, and at 3 and 12 months follow up. Additionally, a subset of participants will undergo objective assessment of physical activity pattern and sedentary behaviours with an accelerometer at baseline and after 3 and 12 months.",[116],"Osteoporosis",[118,119,120,121,122,123,124],"osteoporosis","patient education","self-care","health related quality of life","HRQoL","internetbased","digital","2026-03-15",{"date":127,"type":37},"2026-03-17",{"date":129,"type":37},"2026-01-27",{"date":131,"type":21},"2028-10-20",{"name":43,"class":44},7,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":158},"100422659","coronary-ct-angio-evaluating-graft-patency-in-acs-patients-treated-with-dapt-or-single-asa-after-cabg-cocap-100422659","NCT04783701","Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)","Inclusion Criteria:\n\n* Previously included in TACSI-trial\n\nExclusion Criteria:\n\n* Highly irregular heart rhythm (i.e. atrial fibrillation)\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C45ml\u002Fmin\u002F1,73m2\n* Body weight \\>120 kg\n* Previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based contrast agents\n* Not able to communicate\n* Not willing to participate",{"count":141,"type":21},360,"The purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute coronary syndrome (ACS) treated with coronary artery bypass surgery (CABG). Follow up time is 12-36 months postoperatively and the patency will be evaluated with coronary computed tomography angiography (CCTA)",[144,145],"Acute Coronary Syndrome","Coronary Bypass Stenosis",[147,148,149,150],"Acute coronary syndrome","Coronary bypass surgery","Coronary computed tomography angiography","Antiplatelet therapy","2025-12-14",{"date":153,"type":37},"2025-12-19",{"date":155,"type":37},"2021-05-17",{"date":125,"type":21},{"name":43,"class":44},6,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":101},"100614091","therapeutic-outcomes-of-using-complementary-hand-based-treatment-in-diabetes-100614091","NCT07275086","Therapeutic Outcomes of Using Complementary Hand-based Treatment in Diabetes","Therapeutic Outcomes of Using Complementary Hand-based Treatment in Diabetes (TOUCH-D): A Pilot Single-group Feasibility Study Evaluating Biological and Psychological Effects of Swedish Massage in Adults With Type 1 Diabetes.","TOHCD-D","Inclusion Criteria:\n\n* Adults (≥18 years) with type 1 diabetes ≥ 1 year\n* Able to attend two assessment visits at Vrinnevi Hospital\n* Uses CGM or equivalent system\n* Able to communicate in Swedish and provide consent\n\nExclusion Criteria:\n\n* Severe diabetes complications (e.g., advanced neuropathy)\n* Acute psychiatric disorder requiring treatment\n* Contraindications to massage (e.g., thrombosis, fever, infection, recent surgery)",{"count":168,"type":21},20,[24],"This pilot study evaluates potential biological and psychological effects of Swedish massage in adults with type 1 diabetes. Massage may influence stress-related mechanisms, such as hypothalamic-pituitary-adrenal (HPA) axis activity and inflammation, which are linked to impaired insulin sensitivity and glycemic control. Twenty participants with type 1 diabetes will receive weekly 45-60-minute Swedish massage sessions for five weeks. Biological outcomes include HbA1c, fasting glucose, copeptin, hs-CRP, IL-6, and TNF-α. Glycemic variability will be assessed using continuous glucose monitoring (CGM). Psychological outcomes include perceived stress (PSS-10) and anxiety (GAD-7). The study aims to explore feasibility, acceptability, and preliminary within-group effects on stress regulation and glycemic balance",[172],"Diabetes Mellitus, Type 1","NOT_YET_RECRUITING","2025-11-28",{"date":176,"type":37},"2025-12-10",{"date":178,"type":21},"2026-09-01",{"date":180,"type":21},"2027-02-01",{"name":43,"class":44},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":101},"100452263","phase-2-antibiotic-impregnated-bone-graft-to-reduce-infection-in-hip-replacement-100452263","NCT05169229","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. The ABOGRAFT Trial","ABOGRAFT","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Hip arthroplasty requiring bone graft\n3. Willing to provide informed consent.\n4. For women of childbearing potential; a negative pregnancy test prior to reoperation.\n\nExclusion Criteria:\n\n1. Ongoing prosthetic joint infection\n2. Known allergies and contraindications for the use of vancomycin or tobramycin\n3. Mental inability, reluctance, or language difficulties that according to investigator judgement, result in difficulty understanding the meaning of study participation\n4. Expected difficulties to complete 2-year follow-up\n5. Females of child bearing potential not using contraception\n6. Pregnant females\n7. Nursing females",{"count":191,"type":21},1100,[57,193],"PHASE3","Total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. Periprosthetic joint infection (PJI) is the most common and devastating complication after total hip replacement (THR). Between 0.5 to 2% of primary THR (first time hip replacement), and 8-10% of revision THR (replacement of a hip prosthesis) will become infected.1 The introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary THR by half.2 Unfortunately, cement can't always be used in relevant quantities.\n\nThe number of primary and revision surgeries of the hip is projected to increase dramatically. Therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision THR in addition to antibiotics loaded cement is urgent.\n\nImpacted morselized bone allograft is often used in (revision) THR to fill bone defects. Morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. THR revision surgeries). Nonetheless, a pivotal trial to support its use in THR is lacking. The aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (AIBG) decreases the risk of infection after hip arthroplasty compared to controls treated with placebo impregnated bone graft. Patients scheduled for elective THR will be randomized to receive AIBG or a placebo impregnated bone graft. The primary outcome variable will be the number of re-operations due to infections and PJI diagnoses 2 years postoperative.",[196,197,198,199],"Arthroplasty, Replacement, Hip","Osteoarthritis, Hip","Antibiotic Resistant Infection","Prosthetic Joint Infection","2025-07-17",{"date":202,"type":37},"2025-07-22",{"date":204,"type":37},"2022-04-01",{"date":206,"type":21},"2031-12",{"name":43,"class":44},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":101},"100361670","clinical-decision-support-for-familial-hypercholesterolemia-100361670","NCT03989167","Clinical Decision Support for Familial Hypercholesterolemia","Clinical Decision Support for Familial Hypercholesterolemia: a Cluster Randomized Trial in the Primary Care Setting","CDS-FH","Inclusion Criteria\n\n* Primary care centers in the county of Östergötland.\n\nExclusion Criteria\n\n* Primary care centers not using the Cambio Cosmic Electronic Health Record System.","80 Years",{"count":218,"type":21},460000,[24],"A cluster randomized study in the primary care setting to evaluate a computer-based clinical decision support system to aid in the identification and management of patients with FH. The primary outcome of the study is the number of patients diagnosed with FH thirty-six months after study initiation.",[222,223],"Hypercholesterolemia, Familial","Clinical Decision Support",[222,225,226],"Primary care","Clinical decision support","2024-11-22",{"date":229,"type":37},"2024-11-26",{"date":231,"type":37},"2022-12-06",{"date":233,"type":21},"2025-12-06",{"name":43,"class":44},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":101},"100536837","phase-1-evaluation-of-metastatic-disease-and-oncological-treatment-in-patients-with-colon-cancer-using-zebra-fish-avatars-100536837","NCT06270017","Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars","Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer","ZEBRA-COLON","Inclusion Criteria:\n\n* Colon cancer planned for radical colon resection signed informed consent\n\nExclusion Criteria:\n\n* Not willing to participate",{"count":244,"type":21},300,[246,57],"PHASE1","In order to improve and individualize cancer treatment personalized treatments developed much further. Colon cancer is treated with surgery and thereafter adjuvant oncological treatment. The selection of chemotherapy is today mainly done according to best guess. Today only a small fraction of oncological treatment may be known to be effective in a person before treatment start, most often it is trial and error. A fast reliable system for looking at response to different treatments in each unique patient is much needed and would, if successful, completely change the way we give oncological treatment today. This system would also be possible to use to evaluate new treatments and if successful, implement in the clinical setting. In this project we will implant a part of the patient's tumour tissue into a zebrafish embryo and evaluate tumour growth and frequency of metastatic disease as well as response to given oncological treatment.\n\n2.2 Objective: The objective of this project is to explore the usefulness of zebrafish (Danio Rerio) embryo models to determine tumor biology and treatment response in colon cancer. An overarching goal would be, before start of any oncological treatment in a patient, to have evaluated the response of oncological treatment in the zebrafish avatar and only treat with a combination of drugs known to have effect against the patient's own tumour.\n\n2.3 Study design: This protocol describes a series of prospective studies in different cohorts of patients with colon cancer to investigate the applicability of zebrafish embryo models. The common denominator of the sub-studies is prospective collection of tumor tissue implanted in zebrafish embryos in order to evaluate if the model is robust enough for growing colon cancer tissue and evaluate growth pattern and response to chemotherapy. This study protocol is designed according to and in adherence with the SPIRIT guidelines.\n\n2.4 Intervention: In all sub-studies the intervention is inoculation of tumor cells in zebrafish embryos followed by observation of tumor behavior and testing of treatments.",[249],"Colon Cancer",[251,252],"drug therapy","Zebra fish embryo model","2024-02-13",{"date":255,"type":37},"2024-02-21",{"date":257,"type":37},"2022-01-10",{"date":41,"type":21},{"name":43,"class":44},""]